GSK announces positive results from phase III trial of Nucala ...
2024年9月6日 · GSK plc (LSE/NYSE: GSK) today announced positive headline results of MATINEE, the phase III clinical trial evaluating Nucala (mepolizumab), a monoclonal antibody …
GSK says Nucala hits the target in new COPD trial
2 天之前 · GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial.
US FDA accepts GSK’s submission for the use of Nucala …
2024年12月9日 · GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has accepted for review, data from the MATINEE study to support the …
GSK’s asthma blockbuster Nucala secures win in COPD Phase III trial
2024年9月6日 · GSK’s asthma drug Nucala (mepolizumab) has met the primary endpoint in a Phase III trial treating patients with chronic obstructive pulmonary disease (COPD). Data from …
GSK's Nucala gains US use in rare autoimmune disease
2025年1月12日 · GlaxoSmithKline’s Nucala (mepolizumab) has gained a new FDA approval for the rare autoimmune disease eosinophilic granulomatosis with polyangiitis (EGPA).
GSK antibody drug reduces COPD attacks in trial | BioPharma Dive
2024年9月6日 · GSK on Friday said its Nucala medicine succeeded in a Phase 3 study of patients with chronic obstructive pulmonary disease, offering the British drugmaker another shot at an …
GSK’s Nucala Gains Approval in China for CRSwNP - Yahoo Finance
2025年1月4日 · GSK announced that its monoclonal antibody, Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with nasal polyps (CRSwNP), …
FDA Accepts Nucala for COPD Review - Medthority
2024年12月14日 · GSK plc announced the FDA has accepted for review, data from the MATINEE study to support the regulatory review process to obtain a new indication for the use of Nucala …
GSK Nucala succeeds in Phase 3 COPD trial (NYSE:GSK)
2024年9月6日 · GSK (NYSE:GSK) announced Friday that its asthma therapy Nucala (mepolizumab) reached the main goal in a Phase 3 trial for patients with chronic obstructive …
FDA to review GSK’s Nucala for COPD - Pharmaceutical Technology
2024年12月10日 · The US Food and Drug Administration (FDA) has accepted a submission from GSK to review a new indication of Nucala (mepolizumab) as an add-on maintenance treatment …